A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2010

Conditions
Primary Refractory Neuroblastoma
Interventions
BIOLOGICAL

MAb-3F8

BIOLOGICAL

Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

BIOLOGICAL

13-cis-Retinoic Acid

Trial Locations (15)

10467

Children's Hospital at Montefiore, The Bronx

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20057

Georgetown Medical Center, Washington D.C.

27705

Duke University Medical Center, Durham

33701

All Children's Hospital in Florida, St. Petersburg

43205

Nationwide Childrens Hospital, Columbus

55404

Children's Hospitals and Clinics of Minnesota, Minneapolis

70118

LSU Health Sciences Center; Children's Hospital, New Orleans

73104

University of Oklahoma Cancer Center, Oklahoma City

75230

US Oncology, Dallas

77030

The University of Texas M.D. Anderson Cancer Center, Houston

84113

University of Utah Medical Center, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

92123

Rady Children's Hospital of San Diego, San Diego

05405

Vermont Cancer Center, Burlington

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT00969722 - A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | Biotech Hunter | Biotech Hunter